Positive Phase III data on the prostate cancer drug Xtandi (enzalutamide) in an expanded indication will take some of the edge off at Pfizer Inc., where the brand's near-term growth prospects fizzled right after the expensive acquisition of Medivation Inc.
Pfizer and Xtandi marketing partner Astellas Pharma Inc. announced positive top-line data from PROSPER Sept. 14. The results showed that non-metastatic, castration-resistant prostate cancer (CRPC) patients treated with Xtandi...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?